Oral Contraceptives and the Risk of Myocardial Infarction | Zendy

Bea C. Tanis | Zendy; Maurice A. A. J. van den Bosch | Zendy; Jeanet M. Kemmeren | Zendy; V. Manger Cats | Zendy; Frans M. Helmerhorst | Zendy; Ale Algra | Zendy; Yolanda van der Graaf | Zendy; Frits R. Rosendaal | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Oral Contraceptives and the Risk of Myocardial Infarction

Author(s) -

Bea C. Tanis,

Maurice A. A. J. van den Bosch,

Jeanet M. Kemmeren,

V. Manger Cats,

Frans M. Helmerhorst,

Ale Algra,

Yolanda van der Graaf,

Frits R. Rosendaal

Publication year - 2001

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa003216

Subject(s) - medicine , desogestrel , odds ratio , gestodene , myocardial infarction , confidence interval , population , gynecology , risk factor , obstetrics , family planning , environmental health , research methodology

An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some, but not all, studies. We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research